Cargando…
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer
Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton‐interfering pharmacophores, in testicular...
Autores principales: | Steinemann, Gustav, Dittmer, Alexandra, Schmidt, Jacob, Josuttis, David, Fähling, Michael, Biersack, Bernhard, Beindorff, Nicola, Jolante Koziolek, Eva, Schobert, Rainer, Brenner, Winfried, Müller, Thomas, Nitzsche, Bianca, Höpfner, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887589/ https://www.ncbi.nlm.nih.gov/pubmed/31583820 http://dx.doi.org/10.1002/1878-0261.12582 |
Ejemplares similares
-
Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
por: Bär, Sofia Isolde, et al.
Publicado: (2022) -
Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
por: Nitzsche, B, et al.
Publicado: (2010) -
Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
por: Goehringer, Nils, et al.
Publicado: (2021) -
Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023) -
HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)